← 홈

HER2+ 유방암 · PD-1 / PD-L1

5개 · ADC 1048 · Antibody 5323 · CGT 2737 · 다음 갱신 D-13 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 5개
AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4
효능 ORR 76.7%임상시험 90상태 ACTIVE
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody)

Breast Neoplasms · PD-L1

#PD-L1#Antibody#Phase2#항체#면역항체+3
효능 ORR 20%임상시험 3상태 ACTIVE
CGTBiologicstaleGuangzhou Anjie Biomedical Tech…Phase 2

AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells (AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells)

Advanced Breast Cancer; Breast Neoplasm Malignant Female · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleImugene LimitedPhase 1

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · PD-L1

#PD-L1#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING